Literature DB >> 18751393

Abrogation of estrogen receptor signaling augments cytotoxicity of anticancer drugs on CaSki cervical cancer cells.

Moon Y Heo1, Salama A Salama, Nilufar Khatoon, Ayman Al-Hendy, William W Au.   

Abstract

BACKGROUND: We have reported that a gene therapy approach, using a dominant-negative estrogen receptor blocker (DN) gene, can cause cell death in cervical cancer cells in vitro. We investigated the mechanisms for enhanced cell killing when DN was combined with cisplatin (CP) and paclitaxel (TX).
MATERIALS AND METHODS: Cells were transduced with DN at 24 h and/or treated with drugs at 48 h, and harvested at 48 and 72 h after transduction. Effects were determined using the MTT cytotoxic, and TUNEL and caspase-3 activity apoptotic assays.
RESULTS: Each agent induced cytotoxic and apoptotic effects, and activated caspase-3. In the combined treatments, significant synergistic effects were observed based on the MTT and TUNEL assays, but with antagonistic caspase-3 activation effect.
CONCLUSION: The enhanced cell killing effect was mediated by the initiation of new and multiple mechanisms, particularly via caspase-independent pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18751393      PMCID: PMC4477542     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  30 in total

1.  A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.

Authors:  A L Blajeski; T J Kottke; S H Kaufmann
Journal:  Exp Cell Res       Date:  2001-11-01       Impact factor: 3.905

Review 2.  Cervical cancer and use of hormonal contraceptives: a systematic review.

Authors:  Jennifer S Smith; Jane Green; Amy Berrington de Gonzalez; Paul Appleby; Julian Peto; Martyn Plummer; Silvia Franceschi; Valerie Beral
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

3.  Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.

Authors:  P L Judson; J M Watson; P A Gehrig; W C Fowler; J S Haskill
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

Review 4.  Recent advances in understanding the cell death pathways activated by anticancer therapy.

Authors:  Ryungsa Kim
Journal:  Cancer       Date:  2005-04-15       Impact factor: 6.860

5.  Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL.

Authors:  Qiuwei Pan; Bisheng Liu; Jin Liu; Rong Cai; Yigang Wang; Cheng Qian
Journal:  Mol Cell Biochem       Date:  2007-06-19       Impact factor: 3.396

6.  Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.

Authors:  Patricia García-López; Mauricio Rodríguez-Dorantes; Enrique Pérez-Cárdenas; Marco Cerbón; Alejandro Mohar-Betancourt
Journal:  Cancer Chemother Pharmacol       Date:  2004-01-29       Impact factor: 3.333

7.  Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells.

Authors:  Wenguang Zhang; Chuanyou Zhang; Narassa Narayani; Cheng Du; K C Balaji
Journal:  Cancer Lett       Date:  2007-06-07       Impact factor: 8.679

8.  Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines.

Authors:  Yuichiro Oshima; Yasushi Sasaki; Hideaki Negishi; Masashi Idogawa; Minoru Toyota; Toshiharu Yamashita; Takuro Wada; Satoshi Nagoya; Satoshi Kawaguchi; Toshihiko Yamashita; Takashi Tokino
Journal:  Cancer Biol Ther       Date:  2007-07       Impact factor: 4.742

9.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.

Authors:  Dohun Pyeon; Michael A Newton; Paul F Lambert; Johan A den Boon; Srikumar Sengupta; Carmen J Marsit; Craig D Woodworth; Joseph P Connor; Thomas H Haugen; Elaine M Smith; Karl T Kelsey; Lubomir P Turek; Paul Ahlquist
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 10.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

View more
  3 in total

1.  Raloxifene suppress proliferation-promoting function of estrogen in CaSKi cervical cells.

Authors:  Jing-Quan Ma; Xing-Hua Wang; Li-Ping Tang; Xiu-Wei Chen; Ge Lou
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 2.  Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.

Authors:  Ekati Drakopoulou; Nicholas P Anagnou; Kalliopi I Pappa
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 3.  Targeted Gene Delivery Therapies for Cervical Cancer.

Authors:  Ángela Áyen; Yaiza Jiménez Martínez; Houria Boulaiz
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.